These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 15945241)

  • 1. [Pharmacologic prevention of cardiovascular diseases--2005].
    Kancz S
    Orv Hetil; 2005 May; 146(20 Suppl 2):1122-31. PubMed ID: 15945241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents].
    Auer J; Berent R; Weber T; Porodko M; Mayr H; Maurer E; Eber B
    Wien Med Wochenschr; 2001; 151(1-2):13-7. PubMed ID: 11234591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender, ethnicity, and genes in cardiovascular disease. Part 2: implications for pharmacotherapy.
    Schaefer BM; Caracciolo V; Frishman WH; Charney P
    Heart Dis; 2003; 5(3):202-14. PubMed ID: 12783634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidemiology and prevention of cardiovascular diseases].
    Jánosi A
    Orv Hetil; 2005 Apr; 146(15):683-8. PubMed ID: 15895792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug treatment and cost of cardiovascular disease in Australia.
    Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
    Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [20 years of cardiovascular epidemiology. The clinician's viewpoint].
    Bertrand ME
    Rev Epidemiol Sante Publique; 1996 Nov; 44(6):556-62. PubMed ID: 9005491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Secondary medical prevention in patients with peripheral arterial disease.
    Schouten O; Welten GM; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805
    [No Abstract]   [Full Text] [Related]  

  • 8. [Drug therapy in the secondary prevention of atherosclerosis].
    Kettunen R
    Duodecim; 2002; 118(20):2093-101. PubMed ID: 12463000
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease.
    Sigvant B; Wiberg-Hedman K; Bergqvist D; Rolandsson O; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):39-46. PubMed ID: 19237996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sex differences and cardiovascular drugs].
    Løchen ML; Kvan E
    Tidsskr Nor Laegeforen; 2010 Feb; 130(4):382-4. PubMed ID: 20220863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral arterial disease: Pathophysiology, risk factors, diagnosis, treatment, and prevention.
    Muir RL
    J Vasc Nurs; 2009 Jun; 27(2):26-30. PubMed ID: 19486852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
    Gasse C; Jacobsen J; Larsen AC; Schmidt EB; Johannesen NL; Videbaek J; Sørensen HT; Johnsen SP
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in the prescription of cardiovascular prevention drugs in France between 1995 and 2003: factors influencing the gap between evidence base medicine and clinical practice].
    Philippe F; Cambou JP; Danchin N; Thomas D
    Ann Cardiol Angeiol (Paris); 2005 Dec; 54 Suppl 1():S30-6. PubMed ID: 16411649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The best of epidemiology and cardiovascular prevention in 2006].
    Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP
    Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute ischemic coronary artery disease and ischemic stroke: similarities and differences.
    Fisher M; Folland E
    Am J Ther; 2008; 15(2):137-49. PubMed ID: 18356634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitors for the prevention and treatment of cardiovascular disease.
    Frishman WH
    Heart Dis; 2000; 2(3):183-4. PubMed ID: 11794142
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cardiovascular pharmacotherapy in old age: How beneficial is it? What does it cost?].
    Gysling E
    Praxis (Bern 1994); 1995 Oct; 84(44):1248-51. PubMed ID: 7491446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular drug therapy in the elderly.
    Aronow WS; Frishman WH; Cheng-Lai A
    Cardiol Rev; 2007; 15(4):195-215. PubMed ID: 17575484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.